Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurodegener Dis. 2008;5(1):27-31.

Campath-1H treatment of multiple sclerosis.

Author information

1
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. jls53@medschl.cam.ac.uk

Abstract

Campath-1H is a humanised monoclonal antibody that targets CD52, a cell surface protein expressed on lymphocytes, monocytes and eosinophils. A single dose of Campath-1H leads to a rapid and profound lymphopenia. Campath-1H has been used in Cambridge as an experimental treatment of multiple sclerosis for more than 15 years. Here, we summarise our clinical and laboratory findings, describing how this prototypical 'bench to bedside' therapy continues to inform basic science, revealing aspects of the pathogenesis of multiple sclerosis and autoimmunity.

PMID:
18075272
DOI:
10.1159/000109935
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center